Candel Therapeutics Inc Total Liabilities
Candel Therapeutics Inc total liabilities. Based on the latest financial reports, Candel Therapeutics Inc (CADL) has total liabilities worth $63.89 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Candel Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Candel Therapeutics Inc (2019–2025)
Total liabilities of Candel Therapeutics Inc from 2019 to 2025. This chart illustrates how Candel Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Candel Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Candel Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sumber Global Energy Tbk Pt
JK:SGER
|
Indonesia | Rp2.80 Trillion |
|
Aeva Technologies, Inc. Common Stock
NASDAQ:AEVA
|
USA | $159.71 Million |
|
uPI Semiconductor Corp
TW:6719
|
Taiwan | NT$2.87 Billion |
|
Hingham Institution for Savings
NASDAQ:HIFS
|
USA | $4.06 Billion |
|
Hangzhou Huning Elevator Parts Co Ltd
SHE:300669
|
China | CN¥129.21 Million |
|
Liaoning Hongyang Energy Resource Invest Co Ltd
SHG:600758
|
China | CN¥7.72 Billion |
|
Royce Micro Cap Closed Fund
NYSE:RMT
|
USA | $20.93 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Candel Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Candel Therapeutics Inc asset portfolio.
Liquidity & Leverage Metrics
Candel Therapeutics Inc Total Liabilities Ratios Explained
Candel Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 28.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Candel Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Candel Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Candel Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $73.27 Million | +80.75% |
| 2024-12-31 | $40.54 Million | +42.46% |
| 2023-12-31 | $28.46 Million | -7.63% |
| 2022-12-31 | $30.80 Million | +22.89% |
| 2021-12-31 | $25.07 Million | -59.47% |
| 2020-12-31 | $61.84 Million | +14.66% |
| 2019-12-31 | $53.94 Million | -- |
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of … Read more